U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07006246) titled 'Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa' on March 25.
Brief Summary: This is a funded implementation study designed to evaluate the efficacy of recruiting and retaining high-risk individuals on pre-exposure prophylaxis (PrEP) within multiple private pharmacies (and online platforms in South Africa)
Study Start Date: May 19, 2023
Study Type: INTERVENTIONAL
Condition:
HIV Infection
Intervention:
DRUG: Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)
Tenofovir disoproxil fumarate + emtricitabine/ lamivudine Dosage Formulation: 300 mg / 200 mg (300mg) fixe...